Examiner-Initiated Interview Summary	Application No.	Applicant(s)
	10/577,861	CARLIN ET AL.
	Examiner	Art Unit
	GINNY PORTNER	1645
All Participants: Status of Application: <u>pending</u>		
(1) <u>GINNY PORTNER(PTO)</u> .	(3)	
(2) Mr. Richard Fichter, Reg. 26,382.	(4)	
Date of Interview: 9 June 2009	Time: <u>11:30; 12:30</u>	
Type of Interview:  ☐ Telephonic ☐ Video Conference ☐ Personal (Copy given to: ☐ Applicant ☐ Applicant's representative)  Exhibit Shown or Demonstrated: ☐ Yes ☐ No If Yes, provide a brief description:		
Part I.		
Rejection(s) discussed:		
Claims discussed: all of record		
Prior art documents discussed: na		
Part II.		
SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED: See Continuation Sheet		
Part III.		
<ul> <li>It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.</li> <li>It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.</li> </ul>		
/Ginny Portner/ Examiner, Art Unit 1645 (A	pplicant/Applicant's Representati	ive Signature – if appropriate)
· ·	*	

Application No. 10/577,861

Continuation of Substance of Interview including description of the general nature of what was discussed: claim identifiers were clarified as they did not correspond to Applicant's election; clarified the elected invention and the claims that read on the elected invention. The elected species is species A for examination. Claims 1,4,8-10 and 12 are under examination. The newly submitted claims 15-17 read on species B and are withdrawn from consideration as being directed to a non-elected species of invention. Additional claims that read on species B were also clarified, specifically cliams 13, 5 and 14 which are the combination of LTB signal peptide together with CTB.